Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 8/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.55 |
| ▸ | CDK9 | P50750 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284633 | 0.89 | PDK4 (0.61) | PDK4GRM5GRM1HTR6JAK1 | |
| SCHEMBL6847847 | 0.87 | PDK4 (0.69) | PDK4GRM5GRM1HTR6JAK1 | |
| SCHEMBL6811252 | 0.86 | PDK4 (0.57) | PDK4GRM5GRM1HTR6JAK1 | |
| SCHEMBL19284582 | 0.85 | PDK4 (0.56) | PDK4GRM5GRM1HTR6JAK1 | |
| SCHEMBL6812374 | 0.83 | MAPT (0.44) | CDK9CCNT1HTR6JAK1NAMPT | |
| SCHEMBL13993111 | 0.82 | GRM1 (0.57) | PDK4GRM5GRM1CDK9CCNT1 | |
| SCHEMBL13993112 | 0.82 | GRM1 (0.57) | PDK4GRM5GRM1CDK9CCNT1 | |
| SCHEMBL16434777 | 0.81 | GRM1 (0.56) | PDK4GRM5GRM1CDK9CCNT1 | |
| SCHEMBL19297116 | 0.81 | PDK4 (0.59) | PDK4GRM5GRM1HTR6JAK1 | |
| SCHEMBL2880379 | 0.81 | GRM1 (0.55) | PDK4GRM5GRM1CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | PDK4 3535/4885GRM5 3361/4885GRM1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.